search

Active clinical trials for "Macular Degeneration"

Results 121-130 of 1337

QA102 Phase II Study in Subjects With Dry AMD

Dry Age-related Macular Degeneration

This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of GA or CNV in high-risk eyes.

Active35 enrollment criteria

Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in...

Stargardt Disease 1

The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1

Active10 enrollment criteria

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab...

Neovascular Age-related Macular Degeneration (nAMD)

The purpose of this study is to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated with brolucizumab. This study is being conducted as part of the post-marketing regulatory commitment to the Indian Health authority.

Active10 enrollment criteria

Stereotactic Radiotherapy for Wet AMD (STAR)

Neovascular (Wet) Age-related Macular Degeneration (AMD)

This study investigates the use of radiation to treat wet age-related macular degeneration (AMD). The radiation is delivered using a robotically controlled device that projects overlapping beams of radiation onto the macula, the part of the eye that is affected by wet AMD. Participants will be randomized to receive radiation (stereotactic radiotherapy) or simulated placebo treatment (sham control). They will be followed up regularly for two years, and then again at the end of three and four years for a safety visit. Participants will also receive injections of ranibizumab (Lucentis) into their eye if their wet AMD is active. Ranibizumab is the standard anti-VEGF agent that is used to treat wet AMD. The study aims to determine if stereotactic radiosurgery can maintain vision and reduce the need for such regular anti-VEGF injections.

Active24 enrollment criteria

Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related...

Age-Related Macular Degeneration

Background: Age-related macular degeneration (AMD) is the main reason older people lose their vision. It affects the macula, the center of the retina needed for sharp, clear vision. Researchers want to see if an antibiotic can help people with an advanced form of AMD, Geographic Atrophy (GA). Objective: To see if minocycline is safe for people with GA and if it helps preserve their vision. Eligibility: People age 55 and older who have GA in at least one eye. Design: Participants will be screened with physical exam, medical history, blood tests, and eye exam. Participants will take minocycline. They will take 1 pill twice a day for at least 3 years. Participants will have a minimum of 11 study visits. (But they are not every 3 months.). At each visit, participants will have a medical history. They may have: Blood tests. Eye exam. Vision, eye pressure, and eye movements will be checked. The pupils may be dilated. The inside of the eyes may be photographed. Their thyroid gland felt while they swallow. Microperimetry. They will sit in front of a computer and press a button when they see a light on the screen. Fluorescein angiography. An intravenous line (IV) will be placed in an arm vein. A dye called fluorescein will be placed in the IV and travel through the veins to the blood vessels in the eyes. A camera will take pictures of the dye as it flows through the eye blood vessels.

Active47 enrollment criteria

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants...

Macular DegenerationGeographic Atrophy

Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).

Active12 enrollment criteria

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related...

Wet Macular Degeneration

This is a study in people with an eye disease called wet age-related macular degeneration (wAMD). The purpose of the study is to find out how well different doses of a medicine called BI 836880 are tolerated. People can participate if they are at least 55 years old and if they have new blood vessels in their eyes despite treatment (anti-VEGF therapies). The study has 2 parts. In the first part, people get only 1 dose of BI 836880. This part takes 6 weeks. In the second part, people get 3 times the same dose of BI 836880. This part takes 6 months. BI 836880 is injected into the eye. During the entire study doctors regularly check the health of the participants.

Active46 enrollment criteria

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Neovascular Age-related Macular Degeneration

To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).

Active9 enrollment criteria

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects...

Age-Related Macular DegenerationNeovascular Age-related Macular Degeneration3 more

The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.

Active17 enrollment criteria

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

Wet Age-related Macular Degeneration

This is a randomized, double-blind, two-group parallel, positive-controlled clinical Phase I trial comparing the safety, pharmacokinetics, pharmacodynamics and efficacy of CMAB818 and Lucentis® in patients with wet age-related macular degeneration.

Active29 enrollment criteria
1...121314...134

Need Help? Contact our team!


We'll reach out to this number within 24 hrs